Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Active, not recruiting Not applicable

Healthy Weight Management Project for Overweight and Obesity Children

NCT05482191 · tracked via the Priya Life Science China tracker
Phase
Not applicable
Started
2022-09-01
Last updated
2025-07-09

Condition(s) studied

Obesity

Investigational drug(s) / intervention(s)

Lifestyle intervention

Lifestyle intervention: This intervention programme will target the influencing factors of childhood obesity to influence the knowledge, attitude and behaviours of school children. Students in the treatment group will receive the following interventions: * Develop and implement school policies related to weight loss * Distribute health education materials on diet and exercise to students * Carry out student health education courses * Diet and exercise instruction by professional nutritionist using internet applet * Take part in sports activities that are organized by the sports health teacher during school hours.

Study summary

Childhood obesity is a significant public health concern worldwide. In China, childhood obesity has dramatically increased as the economy has grown quickly over the past decades. Nonalcoholic fatty liver disease (NAFLD) is tightly associated with obesity, in China, the prevalence of NAFLD in obesity children is 40.0%,the main interventions for NAFLD are lifestyle interventions. Effective strategies to helping students lose weight and alleviate NAFLD through lifestyle interventions may help promote the physical and mental health of obese students.

This study aimed (1)to assess the effectiveness of the intervention compared with the usual practice in treating childhood overweight and obesity; (2) to determine the sustainability of the treatment in preventing overweight and obesity; (3) to help alleviate or reverse NAFLD in obesity children.

Children with overweight and obesity in six primary schools in Ningbo City, Zhejiang Province will be seleted and randomly divided into two groups: the treatment group and the usual practice group. The participants of the study were students in the third grade of primary school, and the treatment will last for one academic year. This treatment activity on lifestyle interventions will target the dietary and exercise factors of childhood obesity.

Eligibility

Sex
ALL
Min age
8 Years
Max age
10 Years
Healthy volunteers
Accepted
Inclusion Criteria: * parents agree and support their children's weight loss, and students and parents have informed consent; * students in third grade aged 8 and 10 years old; * students with childhood overweight/obesity defined according to the criteria for Chinese children and adolescents. Exclusion Criteria: * medical history of heart disease, hypertension, diabetes, tuberculosis, asthma, hepatitis or nephritis; * obesity caused by endocrine diseases or side effects of drugs; * abnormal physical development like dwarfism or gigantism; * physical deformity such as severe scoliosis, pectus carinatum, limp, obvious O-leg or X-leg; * inability to participate in school sport activities; * a loss in weight by vomiting or taking drugs during the past 3 months.

Primary outcome measure(s)

  • change in body mass index (BMI) — 3 months,9 months , 24 months and 36 months
    * weight and height will be combined to report BMI in kg/m\^2 * caculated by terminal value minus baseline value
  • change in controlled attenuation parameters (CAP) — 3 months,9 months , 24 months and 36 months
    * CAP will be detected by Fibroscan * caculated by terminal value minus baseline value
  • Change in liver stiffness measurement (LSM) — 3 months,9 months , 24 months and 36 months
    * LSM will be detected by Fibroscan * caculated by terminal value minus baseline value

Trial sites (1)

FacilityCityRegionStatus
Ningbo First Hospital Ningbo China
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05482191 on ClinicalTrials.gov ↗ ← All trials in China